NSE: ZYDUSLIFE · 22 October 2026
- Zydus Lifesciences Ltd shares moved upward during the session, trading up 1.58% at ₹1135.00 compared to the previous close of ₹1117.30. The stock moved within an intraday range of ₹1100.30 to ₹1138.50, opening lower at ₹1111.00.
- Zylidac Bio, a biologics CDMO within the Zydus Lifesciences group, announced a partnership with Prolific Machines to scale Prolific's light-controlled cell line development platform from early development to GMP production. The technology aims to deliver higher yields and precise process control for complex biologics using Zylidac's Emeryville facility. Operations will begin with tech transfer at 50-liter scale before scaling to 250 liters and commercial manufacturing.
- Trading volume was 0.87 times the 20-day average daily volume.
Why is Zydus Lifesciences share price rising on 22 October 2026?
Zydus Lifesciences Ltd shares moved upward during the session, trading up 1.58% at ₹1135.00 compared to the previous close of ₹1117.30. The stock moved within an intraday range of ₹1100.30 to ₹1138.50, opening lower at ₹1111.00.
The broader market experienced downward pressure during the session, with the Nifty falling 0.88%, while the sector benchmark Nifty Pharma held relatively resilient with a minor decline of 0.07%. Against this backdrop, the stock outperformed the broader benchmark indices, demonstrating relative strength within the pharmaceutical sector. Over recent periods, the stock has posted a 5-day return of 0.92% and a 20-day return of -2.35%.
Recent developments surrounding the company include a partnership announcement between Zylidac Bio, a fully integrated biologics CDMO within the Zydus group, and Prolific Machines to scale a next-generation biologics manufacturing platform to GMP production. Additionally, the company recently received USFDA approval for the Estradiol and Levonorgestrel Transdermal System with eligibility for 180-day competitive generic therapy exclusivity, alongside concluding a USFDA inspection at its Moraiya manufacturing plant with 5 observations. While these operational updates provide underlying business context, no single catalyst was directly linked to today's price movement.
13.58 lakh shares traded by 22 October 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 15.68 lakh shares (0.87 times). The five-day average daily volume was 12.12 lakh shares. Separately, the NSE report for 22 October 2026 showed 6.94 lakh shares delivered, representing 51.11% of that day’s traded volume. The same report recorded 34,252 trades.
The stock gained 1.58% during a session when broader benchmark indices declined, supported by stable delivery participation. While recent operational updates provide broader business context, no single confirmed news item directly drove today's move.
Latest Company Developments
Zylidac Bio, a biologics CDMO within the Zydus Lifesciences group, announced a partnership with Prolific Machines to scale Prolific's light-controlled cell line development platform from early development to GMP production. The technology aims to deliver higher yields and precise process control for complex biologics using Zylidac's Emeryville facility. Operations will begin with tech transfer at 50-liter scale before scaling to 250 liters and commercial manufacturing.
This partnership expands Zydus' advanced manufacturing capabilities in complex biologics and positions its CDMO segment to handle high-yield client programs.
Zydus Lifesciences announced that the USFDA granted final approval for its Abbreviated New Drug Application for the Estradiol and Levonorgestrel Transdermal System, designated with Competitive Generic Therapy status and eligibility for 180-day exclusivity. The product, used for menopausal symptoms and osteoporosis prevention, had annual U.S. sales of approximately USD 45.7 million as of August 2026 and will be manufactured at the Moraiya plant.
CGT exclusivity and final USFDA approval offer an opportunity for market penetration and revenue expansion in the U.S. women's health segment.
The USFDA conducted an inspection at the company's manufacturing facility located at Moraiya, Ahmedabad, from October 5 to October 13, 2026. The inspection concluded with 5 observations, and the company stated it will work closely with the regulator to address them expeditiously.
Regulatory compliance at core manufacturing sites remains vital for maintaining uninterrupted export supplies and securing future product approvals in regulated markets.
a press release dated October 21, 2026, titled "Zylidac Bio and Prolific Machines Partner to Scale Prolific s Next-Generation Biologics Manufacturing Platform to GMP Production".
a press release dated August 31, 2026, titled "Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 6.88% on 30 September 2026. This compares with 5.12% on 30 June 2026, a change of +1.76 percentage points.
The filing reported 41 MF/UTI holders.
Research & Brokerage Views
Maintained an Outperform rating following business developments and earnings performance.
Raised target price while maintaining a Sell rating on valuation considerations.
Maintained a Neutral rating citing limited upside potential from prevailing levels.
What to Watch Next
- Execution and commercial progress of the Zylidac Bio and Prolific Machines partnership
- Commercial launch and market uptake of the Estradiol and Levonorgestrel Transdermal System in the U.S.
- Resolution and follow-up responses regarding the 5 USFDA observations at the Moraiya manufacturing plant
- Upcoming financial results scheduled for November 4, 2026
Other Dated Coverage
- Zydus Lifesciences in Focus After Sri Lanka Plant Agreement; What to Watch | 16 October 2026 — 16 October 2026
- Zydus Lifesciences in Focus: USFDA Concludes Moraiya Plant Inspection | 15 October 2026 — 15 October 2026
- Zydus Lifesciences in Focus After USFDA Moraiya Inspection Observations | 14 October 2026 — 14 October 2026
More Zydus Lifesciences news and dated analysis →
Frequently Asked Questions
What is the latest Zydus Lifesciences company news?
Zylidac Bio, a biologics CDMO within the Zydus Lifesciences group, announced a partnership with Prolific Machines to scale Prolific's light-controlled cell line development platform from early development to GMP production. The technology aims to deliver higher yields and precise process control for complex biologics using Zylidac's Emeryville facility. Operations will begin with tech transfer at 50-liter scale before scaling to 250 liters and commercial manufacturing.
How strong was Zydus Lifesciences’s trading volume?
13.58 lakh shares traded, 0.87 times the 20-day average daily volume. The price and volume data are dated 22 October 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.